The producer of Ozempic was suggested to record the intense eye situation as a facet impact
The European Medicines Company (EMA) has concluded that semaglutide-based drugs – together with Ozempic, Wegovy, and Rybelsus – improve the chance of a critical eye situation that may result in sudden imaginative and prescient loss.
Following a complete security evaluation, the EMA’s Pharmacovigilance Threat Evaluation Committee (PRAC) decided on Friday that non-arteritic anterior ischemic optic neuropathy (NAION) must be listed as a “very uncommon” facet impact of semaglutide – the primary element of weight-loss and anti-diabetic medicine produced by Novo Nordisk.
The EU well being watchdog’s evaluation, initiated in January 2025, analyzed knowledge from scientific trials, post-marketing surveillance, and medical literature. Findings recommend that adults with kind 2 diabetes taking semaglutide have roughly twice the chance of creating NAION in comparison with these not on the medicine. The “very uncommon” facet impact classification signifies that the situation could have an effect on as much as 1 in 10,000 customers.
NAION is the second most typical explanation for optic nerve-related blindness after glaucoma. Sufferers experiencing sudden imaginative and prescient loss or quickly worsening eyesight whereas on semaglutide are suggested to hunt rapid medical consideration and discontinue use if NAION is identified.
The Denmark-based firm Novo Nordisk owns the patent on semaglutide, a GLP-1 receptor agonist used for managing kind 2 diabetes and weight problems. It capabilities by enhancing insulin secretion and selling a sense of fullness, thereby aiding in blood sugar management and weight administration.
A latest research additionally indicated that Ozempic and comparable drugs could improve the chance of kidney most cancers. Nonetheless, the medicine reportedly decrease the chance of greater than a dozen different cancers, suggesting their general profit should outweigh the hazards. Moreover, the EMA beforehand investigated stories of suicidal ideas related to semaglutide use, although no definitive causal relationship was established.
The EMA’s suggestions will now be reviewed by the Committee for Medicinal Merchandise for Human Use (CHMP) earlier than a closing choice is adopted by the European Fee. Novo Nordisk, which was dethroned as Europe’s most beneficial firm earlier this yr, has acknowledged its dedication to affected person security and is working with the EMA to replace product labels accordingly.
You possibly can share this story on social media:
